China-based Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488) has announced that the National Medical Products Administration (NMPA) has accepted a clinical trial filing for its Category 1 drug, ACC017, for the treatment of HIV-1 infection in combination with other antiretroviral drugs.
Mechanism and Pre-Clinical Findings
ACC017 is a human immunodeficiency virus (HIV) integrase strand transfer inhibitor designed to effectively block the integration of the HIV genome into the host genome DNA by inhibiting HIV integrase activity. Pre-clinical studies have demonstrated that ACC017 possesses a clear mechanism of action, robust antiviral effects, and synergistic effects with other antiretroviral drugs, all within a broad safety window.
Previous Licensing Deal
Aidea Pharma’s anti-HIV drugs, ainuovirine and a combination of ainuovirine, lamivudine, and tenofovir disoproxil, which have been approved in China, were licensed to South Korean firm Kainos Medicine Inc. in April of this year. This licensing agreement underscores the global interest in Aidea Pharma’s innovative approach to HIV treatment.-Fineline Info & Tech
